Dr. Ashwin Singh Parihar sits down with Dr. Louise Emmett to discuss how post-therapy Lutetium-177 PSMA SPECT/CT may help predict overall survival in patients with metastatic castration resistant prostate cancer and shape future treatment decisions. Drawing from the ENZA-p trial run by ANZUP cancer trials group, they explore quantitative imaging, treatment response assessment, adaptive dosing strategies, and the growing role of theranostics in precision oncology.
 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Radiological Society of North America. Innehållet i podden är skapat av The Radiological Society of North America och inte av, eller tillsammans med, Poddtoppen.